Patient related outcomes in a real life prospective follow up study: Allergen immunotherapy increase quality of life and reduce sick days

Karin D Petersen, Christian Kronborg, Jørgen N Larsen, Ronald Dahl, Dorte Gyrd-Hansen, Karin D Petersen, Christian Kronborg, Jørgen N Larsen, Ronald Dahl, Dorte Gyrd-Hansen

Abstract

Background: One fourth of the adult population in Europe suffer from respiratory allergy. Subcutaneous-allergen-specific-immunotherapy (SCIT) has long-term disease modifying effect on disease specific Health-Related Quality of Life (HRQoL). The purpose of this study was to assess the effect of SCIT on alternative disease outcomes in patients with grass-pollen and/or house dust mite induced allergic rhino-conjunctivitis and/or an asthma diagnosis. Focus was on expressing outcomes in terms of generic quality of life (Quality-Adjusted-Life-Years (QALY)) and reductions in sick days.

Methods: The study was a multi-centre study with prospective follow-up. 248 patients were initiated on SCIT. The disease specific Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ) and two generic (HRQoL) instruments 15D and EQ-5D were used at baseline and at follow-up. The outcome measures included change in; disease severity, RQLQ-scores, number of days with symptoms- and number of sick days per year and finally changes in generic HRQoL and thus, QALY. Disease severity was assessed by specialist doctors; severity of rhino-conjunctivitis was classified according to the Allergic Rhinitis and its Impact on Asthma (ARIA) and asthma severity according to the Global Initiative for Asthma (GINA guideline). The remaining outcome measures were assessed by the patients in questionnaires at baseline and at follow-up. An intension to treat approach was applied. For missing items imputation of sample mean base-line values or follow-up values were used after specified criteria. The effect of SCIT on rhino-conjunctivitis and/or asthma diagnoses was analysed at follow-up using three logistic regression models.

Results: The disease severity showed significantly improved disease control. Mean RQLQ-score was reduced from 3.02 at baseline to 2.00 at follow-up. Average annual days with symptoms were reduced from 189 to 145 days whilst annual sick days were reduced from 3.7 to 1.2 days. The 15D-score increased from 0.83 to 0.86 and the EQ-5D-score from 0.70 to 0.77, which indicated an annual gain per patient of 0.03-0.06 QALY.

Conclusions: Allergic patients suffering from rhino-conjunctivitis alone or rhino-conjunctivitis and asthma experience significantly increased HRQoL and they gain 0.03-0.06 QALY, when treated with SCIT for one year.

Trial registration: The study was registered at ClinicalTrials.gov with the identifier: NCT01486498.

Figures

Figure 1
Figure 1
Cumulated grass pollen counts for the three years of the study period and a corresponding flow of the 183 grass pollen allergic patients inclusion- and follow-up year.

References

    1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. EurRespir J. 2004;6:758–764.
    1. Pawankar R, Canonica GW, Holgate ST, Lockey RF. White Book on Allergy. Milwaukee, Wisconsin: World Allergy Organisation (WAO); 2011.
    1. Dahl R, Andersen PS, Chivato T, Valovirta E, de Monchy J. National prevalence of respiratory allergic disorders. Respir Med. 2004;6:398–403. doi: 10.1016/j.rmed.2003.11.015.
    1. Jarvis D, Luczynska C, Chinn S, Potts J, Sunyer J, Janson C, Svanes C. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. J Allergy Clin Immunol. 2005;6:675–682. doi: 10.1016/j.jaci.2005.05.009.
    1. Calderon MA, Demoly P, van Gerth WR, Bousquet J, Sheikh A, Frew A, Scadding G, Bachert C, Malling HJ, Valenta R, Bilo B, Nieto A, Akdis C, Just J, Vidal C, Varga EM, Varez-Cuesta E, Bohle B, Bufe A, Canonica WG, Cardona V, Dahl R, Didier A, Durham SR, Eng P, Fernandez-Rivas M, Jacobsen L, Jutel M, Kleine-Tebbe J, Klimek L. et al.A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy. 2012;6:20. doi: 10.1186/2045-7022-2-20.
    1. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;6:87–93. doi: 10.1067/mai.2001.112027.
    1. Purello-D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, Ricciardi L. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;6:1295–1302. doi: 10.1046/j.1365-2222.2001.01027.x.
    1. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Moller C. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;6:943–948. doi: 10.1111/j.1398-9995.2007.01451.x.
    1. Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care. 2000;6:373–378.
    1. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, Sampson N, Eng B. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;6:1203–1210. doi: 10.1185/030079906X112552.
    1. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr.) 2005;6:296–302. doi: 10.1016/S0301-0546(05)73246-8.
    1. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold - high cost to society. Allergy. 2010;6:776–783.
    1. Jones PW. Quality of life measurement in asthma. Eur Respir J. 1995;6:885–887.
    1. Muldoon MF, Barger SD, Flory JD, Manuck SB. What are quality of life measurements measuring? BMJ. 1998;6:542–545. doi: 10.1136/bmj.316.7130.542.
    1. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;6:364–369. doi: 10.1016/S0091-6749(99)70380-5.
    1. Brooks R, Rabin R, de Charro F. The measurement and evaluation of health status using EQ-5D: A European perspective (Evidence from the EuroQol BIOMED research programme) Dordrecht: Kluwer Academic Publishers; 2003.
    1. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;6:328–336. doi: 10.3109/07853890109002086.
    1. Petersen KD, Kronborg C, Gyrd-Hansen D, Dahl R, Larsen JN, Lowenstein H. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy. 2008;6:284–291. doi: 10.1111/j.1398-9995.2007.01583.x.
    1. Petersen KD, Kronborg C, Gyrd-Hansen D, Dahl R, Larsen JN, Linneberg A. Characteristics of patients receiving allergy vaccination: to which extent do socio-economic factors play a role? Eur J Public Health. 2010;6:323–328.
    1. Petersen KD, Gyrd-Hansen D, Linneberg A, Dahl R, Larsen JN, Lowenstein H, Kronborg C. Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy. Int J Technol Assess Health Care. 2010;6:20–29. doi: 10.1017/S026646230999081X.
    1. Bachert C, Van CP. The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. Chem Immunol Allergy. 2003;6:119–126.
    1. Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'byrne P, Sheffer A. GINA guidelines on asthma and beyond. Allergy. 2007;6:102–112.
    1. Wittrup-Jensen K. Measurement and Valuation of Health-related Quality of Life. Odense: University Press of Southern Denmark; 2006.
    1. Sintonen H. The 15D-measure of health-related quality of life. I. Reliability, validity and sensitivity of its health state descriptive system. Melbourne: National Centre for Health Program Evaluation, working paper 41; 1994.
    1. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health. 2009;6:459–466. doi: 10.1177/1403494809105287.
    1. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;6:717–725. doi: 10.1016/j.jaci.2011.12.973.
    1. Kirkwood BR, Sterne JAC. Medical Statistics. 2. Massachusetts, USA: Blackwell Science Ltd; 2003.
    1. Lunde L. Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients. Eur J Health Econ. 2013;6(3):539–550. doi: 10.1007/s10198-012-0402-y.
    1. Moock J, Kohlmann T. Comparing preference-based quality-of-life measures: results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders. Qual Life Res. 2008;6:485–495. doi: 10.1007/s11136-008-9317-6.
    1. Petersen KD. Impact of allergy and asthma on quality of life and comparison with other diseases. Drugs Today (Barc.) 2008;6:17–18.
    1. Dam Petersen K, Gyrd-Hansen D, Kjaergaard S, Dahl R. Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr.) 2005;6:264–269. doi: 10.1157/13080929.
    1. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;6:468–475. doi: 10.1056/NEJM199908123410702.
    1. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy. 2001;6:301–306. doi: 10.1034/j.1398-9995.2001.00834.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe